Analysts forecast that ContraFect Corp (NASDAQ:CFRX) will report earnings per share (EPS) of ($0.10) for the current quarter, Zacks reports. Zero analysts have issued estimates for ContraFect’s earnings, with estimates ranging from ($0.10) to ($0.09). ContraFect reported earnings per share of ($0.15) in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The company is scheduled to issue its next earnings results on Wednesday, March 21st.
On average, analysts expect that ContraFect will report full year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.33) to ($0.32). For the next financial year, analysts forecast that the company will report earnings of ($0.40) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover ContraFect.
ContraFect (NASDAQ:CFRX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.15.
Institutional investors and hedge funds have recently modified their holdings of the business. Fosun International Ltd purchased a new stake in ContraFect in the third quarter worth about $9,435,000. Birchview Capital LP boosted its stake in shares of ContraFect by 56.5% in the third quarter. Birchview Capital LP now owns 1,135,082 shares of the biotechnology company’s stock worth $1,260,000 after acquiring an additional 410,000 shares during the period. Finally, 683 Capital Management LLC bought a new position in shares of ContraFect in the third quarter worth about $2,886,000. Institutional investors and hedge funds own 62.47% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect ContraFect Corp (CFRX) Will Post Earnings of -$0.10 Per Share” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/27/zacks-analysts-expect-contrafect-corp-cfrx-will-post-earnings-of-0-10-per-share-2.html.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.